Randomised, open-label, phase II trial of paclitaxel, gemcitabine and cisplatin versus gemcitabine and cisplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium

Oncology Reports

Volumn 13, Issue 2, 2005, Pages 283-287

  Lorusso, Vito ^a   Crucitta, Enrico ^a   Silvestris, Nicola ^b   Rosati, G ^c   Manzione, L ^c   De Lena, Mario ^a  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^b G Porfiri Oncology Centre   (Italy)

^c SAN CARLO HOSPITAL   (Italy)

Author keywords

Bladder cancer; Gemcitabine; Paclitaxel

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DEOXYCYTIDINE; DRUG DERIVATIVE; GEMCITABINE; PACLITAXEL;

AGED; ARTICLE; BLADDER TUMOR; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; KIDNEY TUMOR; MALE; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TIME; TRANSITIONAL CELL CARCINOMA; UROTHELIUM;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; CISPLATIN; DEOXYCYTIDINE; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; TIME FACTORS; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 16244363365     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Harker WG, Meyers FJ, Freiha FS, et al: Cisplatin, methotrexate, and vinblastine (CMV): An effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract - a Northern California Oncology Group study. J Clin Oncol 3: 1463-1468, 1985.
2. Sternberg CN, Yagoda A, Scher HI, et al: M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urotelium. J Urol 3: 1463-1468, 1985.
3. Loehrer PJ, Einhorn LH, Elson PJ, et al: A randomised comparison of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma. J Clin Oncol 10: 1066-1073, 1992.
4. Logothetis CJ, Dexeus FH, Finn L, et al: A prospective randomised trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8: 1050-1055, 1990. (Pubitemid 20200193)
5. Tannock I, Gospodarowick M, Connolly J, et al: MVAC chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience. J Urol 142: 289-292, 1989.
6. Hillcoat BL, Raghavan D, Matthews J, et al: A randomised trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of the urothelial tract. J Clin Oncol 6: 706-709, 1989. (Pubitemid 19145590)
7. Gatzemeier U, Shepherd FA, Le Chevalier T, et al: Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study. Eur J Cancer 32: 243-248, 1996.
8. Moore M: Activity of gemcitabine in patients with advanced pancreatic carcinoma. A review. Cancer 78 (Suppl 3): 633-638, 1996.
9. Stadler WM, Kuzel T, Roth B, el al: Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 15: 3394-3398, 1997. (Pubitemid 27485860)
10. Shapiro JD, Millward MJ, Rischin D, et al: Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol 63: 89-93, 1996. (Pubitemid 26337972)
11. Sternberg CN: Gemcitabine in bladder cancer. Semin Oncol 27: 31-39, 2000.
12. Peters GJ, Bergman AM, Ruiz van Haperen VW, et al: Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 22 (Suppl 11): 72-79, 1995.
13. Von der Maase H, Hansen SW, Roberts JT, et al: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 17: 3068-3077, 2000.
14. Fuchs DA and Johnson RK: Cytologic evidence that Taxol, antineoplastic agent from Taxus Brevifolia, acts as a mitotic spindle poison. Cancer Treat Rep 62: 1219-1222, 1978. (Pubitemid 9015338)
15. Rangel C, Niell H, Miller A, et al: Taxol and taxotere in bladder cancer: In vitro activity and urine stability. Cancer Chem Phar 33: 460-464, 1994. (Pubitemid 24082338)
16. Roth B, Dreicer R, Einhorn LH, et al: Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the ECOG. J Clin Oncol 12: 2264-2270, 1994. (Pubitemid 24346693)
17. Gehan EA: The determination of number of patients required in a preliminary and a Follow-up trial of a new chemotherapeutic agent. J Chron Dis 20: 346, 1961.
18. Simon R: Confidence intervals for reporting results of clinical trials. Ann Intern Med 105: 429, 1986.
19. Bellmunt J, Guillem V, Paz-Arcs L, et al: Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. J Clin Oncol 18: 3247-3255, 2000.
20. Bellmunt J, Albancll J, Paz-Ares L, et al: Pre-treatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin and gemcitabine. Cancer 95: 751-757, 2002. (Pubitemid 34839666)
21. Bajorin DF, McCaffrey JA, Dodd PM, et al: Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedules. Cancer 88: 1671-1678, 2000. (Pubitemid 30183153)
22. Hussain M, Vaishampayan U, Du W, et al: Combination paclitaxel, carboplatin and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol 19: 2527-2533, 2001. (Pubitemid 32391224)